Nader Sanai
Clinical trials sponsored by Nader Sanai, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to reach brain tumors in recurrent glioblastoma Results expected Sep 2026 (estimated)
- New smart drug takes aim at Hard-to-Treat brain cancers Results expected Jul 2027 (estimated)
- Can a new pill reach brain tumors and halt their growth? Results expected Jul 2027 (estimated)
-
New hope for brain cancer: drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis trial tests an experimental drug, BGB-58067, in people with a newly diagnosed and aggressive brain cancer called glioblastoma. The drug is designed to work specifically in tumors missing a certain gene (MTAP). The study first checks if the drug reaches the brain and affects …
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug aims to reach brain tumors in recurrent glioblastoma
Disease control Recruiting nowThis early-phase trial tests a drug called BMS-986504 in up to 12 people with recurrent glioblastoma, a severe brain cancer. The drug targets tumors with a specific genetic change (MTAP loss). The study first checks if the drug can reach the brain tumor during surgery, then looks…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a cancer pill slow aggressive brain tumors?
Disease control Recruiting nowThis study tests whether the drug abemaciclib can help people with a fast-growing type of brain tumor called grade 3 meningioma. Participants will receive either the drug or a placebo after standard radiation therapy. The goal is to see if the drug delays tumor growth. About 72 p…
Phase 2 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New smart drug takes aim at Hard-to-Treat brain cancers
Disease control Recruiting nowThis early-phase trial is testing an investigational drug called risvutatug rezetecan in 15 people with recurrent glioblastoma or brain metastases. The drug is designed to seek out and deliver a cancer-killing payload to tumor cells. The study first measures how much drug gets in…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC